Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)

Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 17–18

HOS-130968 · Präparat HOS-096981

17 Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax ↑ 20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-∞ ↑ 100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax ↑ 114% needed. Diclofenac AUC0-∞ ↑ 78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax ↑ 1.7-fold other long-acting opiates Oxycodone AUC0-∞ ↑ 3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax ↑ 31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUCτ ↑ 47% reactions and toxicity related to S-methadone Cmax ↑ 65% methadone, including QTc S-methadone AUCτ ↑ 103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-∞ ↑ 6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 µg/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-∞ ↑ 1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax ↑ 36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUCτ ↑ 61% related to oral contraceptives, in inhibitor] Norethisterone Cmax ↑ 15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUCτ ↑ 53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax ↑ 14% Voriconazole AUCτ ↑ 46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)